Furthermore, ongoing trials aim to evaluate the inhibition of checkpoint kinases (e.g., CDK4/6, CDK1/2) alone or in combination with CT drugs in brain tumors including recurrent and refractory SHH, Group 3/Group 4 MBs (NCT02255461, NCT04023669). This evidence concerns the gene CDK1 and brain neoplasm.